NetworkNewsBreaks – Endonovo Therapeutics, Inc.
Post# of 416
(Total Views: 889)
Posted On: 02/13/2020 3:13:16 PM
NetworkNewsBreaks – Endonovo Therapeutics, Inc. (ENDV) Collaborates with a Stanford University Sponsored Orthopedic Shoulder and Knee Study
Endonovo Therapeutics (OTCQB: ENDV) today announced its collaboration with a Stanford University sponsored Orthopedic Shoulder and Knee Study to determine benefits of Endonovo’s tPEMF SofPulse(R) on pain, medication levels and physical function post-operatively. According to the update, the study will evaluate 76 patients with Active and Sham Comparator groups, measured by visual analog scale (“VAS”), at 10 days after, and will allow surgeons to determine postoperative efficacy of Endonovo’s SofPulse(R) tPEMF portable device. “The study will allow surgeons to determine if PEMF SofPulse(R) therapy is beneficial in reducing patient-reported post-operative pain,” Endonovo CMO, Dr. Nev Zubcevik DO, said in the news release. “Surgeons will be able to make observations on the amount of pain medication taken daily and the physical function outcome scores after surgery and PEMF treatment. Past published clinical efficacy studies for tPEMF SofPulse(R) have shown 2.2X reduction of post-op use of narcotics at 48 hours, 300% reduction of pain scores which relates to nearly a three times faster reduction in the need for pain medication post-op and 275% reduction in inflammation and swelling at 18 hours postoperatively.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Endonovo Therapeutics (OTCQB: ENDV) today announced its collaboration with a Stanford University sponsored Orthopedic Shoulder and Knee Study to determine benefits of Endonovo’s tPEMF SofPulse(R) on pain, medication levels and physical function post-operatively. According to the update, the study will evaluate 76 patients with Active and Sham Comparator groups, measured by visual analog scale (“VAS”), at 10 days after, and will allow surgeons to determine postoperative efficacy of Endonovo’s SofPulse(R) tPEMF portable device. “The study will allow surgeons to determine if PEMF SofPulse(R) therapy is beneficial in reducing patient-reported post-operative pain,” Endonovo CMO, Dr. Nev Zubcevik DO, said in the news release. “Surgeons will be able to make observations on the amount of pain medication taken daily and the physical function outcome scores after surgery and PEMF treatment. Past published clinical efficacy studies for tPEMF SofPulse(R) have shown 2.2X reduction of post-op use of narcotics at 48 hours, 300% reduction of pain scores which relates to nearly a three times faster reduction in the need for pain medication post-op and 275% reduction in inflammation and swelling at 18 hours postoperatively.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Endonovo Therapeutics, Inc. (ENDV) Stock Research Links
Scroll down for more posts ▼